James Frates

5 results

Alkermes’s proprietary products, Vivitrol and Aristada, both saw an increase in net sales in the first quarter

Alkermes made a pretax loss of $72.6 million (€66.8m) in the three months to the end of March 2017. That represents a decrease of 5.75 per cent on the(...)

Richard Pops, Alkermes chief executive, received a lower salary last year. Photograph: Dara Mac Dónaill / The Irish Times

Executives at Irish-headquartered biopharma group Alkermes received lower overall remuneration last year. The group, which is domiciled in Ireland fo(...)

Chief executive of Alkermes Richard Pops in their Dublin offices: the firm’s  net loss  jumped to $77.4 million from $30.7 million. Photograph: Aidan Crawley

Biopharma group Alkermes has reported a sharp increase in its net loss in the first quarter on the back of increased investment in its late-stage pipe(...)

Richard Pops, chief executive  of Alkermes at their Dublin offices. Photograph: Aidan Crawley

Revenue at Irish drug group Alkermes jumped almost 24 per cent in the first three months of the year, to $161.2 million, ahead of analyst expectations(...)

Richard Pops, chief executive of Alkermes: “Our financial results reflect the financial transformation of Alkermes.” Photograph: Aidan Crawley

Alkermes, the company that acquired Elan Drug Technologies, yesterday reported “robust” results for what it called a “remarkable year”. I(...)